TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07401901: Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes

Sponsor: Medtronic MiniMed, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 230 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,739,600

Rescue Site Savings

+$4,448,800

Unlock Full NCT07401901 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07401901 Rescue Dossier →